Kailera Therapeutics公布Hengrui Pharma口服小分子GLP-1受体激动剂HRS-7535/KAI-7535两项III期临床试验积极顶线数据

美股速递
Jul 07

Kailera Therapeutics公司宣布,其合作伙伴Hengrui Pharma研发的口服小分子GLP-1受体激动剂HRS-7535(亦称为KAI-7535)在两项III期临床试验中取得了积极的顶线结果。

这两项关键性研究的数据显示,该候选药物在预设的主要疗效终点上均达到了统计学显著性,展现出令人鼓舞的治疗潜力。作为一款口服制剂,HRS-7535/KAI-7535若成功上市,有望为患者提供比现有注射疗法更为便捷的用药选择。

GLP-1受体激动剂是当前代谢疾病治疗领域的热点,主要应用于2型糖尿病和肥胖症的管理。此次公布的积极数据,进一步验证了该靶点及口服给药途径的可行性,为相关疾病的治疗格局增添了新的可能性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10